SAB begins seasonal flu immunotherapy clinical trial

By The Science Advisory Board staff writers

July 30, 2020 -- SAB Biotherapeutics has begun a phase I clinical trial evaluating SAB-176 for the treatment of seasonal influenza.

SAB-176 is an antiinfluenza human immunoglobulin (IgG) immunotherapy. The fully human polyclonal antibody targets four influenza virus strains and mimics the body's natural way to fight disease. SAB-176 has the ability to adapt to future emerging and mutating seasonal strains, one of the urgent limitations of existing seasonal influenza treatments.

SAB-176 was generated using the company's proprietary DiversitAb platform and is designed to specifically bind to type A and type B influenza viruses. Preclinical testing has demonstrated that the drug has high potency and neutralization against various influenza strains.

The phase I trial is a randomized, double-blind, single ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of the drug as delivered to 27 healthy patients. The phase I study is expected to be completed in early 2021. The study will inform dosage for a phase II trial.

Will SARS-CoV-2 become an endemic seasonal coronavirus?
U.K. virologists have reviewed over 40 studies on SARS-CoV-2 immunity and discussed how this current knowledge about immune responses can inform virus...
Universal flu vaccine R&D collaboration established
Clinical-stage biopharmaceutical company TFF Pharmaceuticals has partnered with researchers at the University of Georgia and University of Texas to evaluate...
Better flu treatments on the way thanks to the discovery of broadly protective antibodies
Research from the National Institutes of Allergy and Infectious Diseases (NIAID) isolated the antibodies from a person sick with the flu five days after...

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter